A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the six months ended June 30, 2026 and June 30, 2025 is as follows (in thousands):


Six Months Ended June 30, 2026	Contingent Consideration Liability Related to the Acquisition of:
	Arkis (1)		Derma Sciences (2)		Surgical Innovations Associates (SIA), Inc. (2)		Total
Balance as of January 1, 2026	$	6,299	$	350	19,400		26,049
Payment	—		—		(17,962)		(17,962)
Change in fair value of contingent consideration liabilities	661		4		(1,438)		(773)
Balance as of June 30, 2026	6,960		354		—		7,314

Short-Term - Accrued expenses and other liabilities	$	3,630	$	—	$	—	$	3,630
Long-Term - Other liabilities	3,330		354		—		3,684
Total	6,960		354		—		7,314


Six Months Ended June 30, 2025	Contingent Consideration Liability Related to the Acquisition of:
	Arkis (1)		Derma Sciences (2)		ACell (2)		Surgical Innovations Associates (SIA), Inc. (2)		Total
Balance as of January 1, 2025	$	12,968	$	2,686	$	3	$	54,000	69,657
Payment	(5,000)		—		—		(18,075)		(23,075)
Change in fair value of contingent consideration liabilities	(627)		(1,451)		—		1,875		(203)
Balance as of June 30, 2025	$	7,341	$	1,235	$	3	$	37,800	46,379

Short-Term - Accrued expenses and other liabilities	$	3,579	$	—	$	—	$	17,700	$	21,279
Long-Term - Other liabilities	3,762		1,235		3		20,100		25,100
Total	7,341		1,235		3		37,800		46,379